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Edited by Stuart FergusonAbstract Kynurenine aminotransferase (KAT) catalyzes the
formation of kynurenic acid (KYNA), the natural antagonist of
ionotropic glutamate receptors. This study tests potential
substrates and assesses the eﬀects of amino acids and keto acids
on the activity of mosquito KAT. Various keto acids, when
simultaneously present in the same reaction mixture, display a
combined eﬀect on KAT catalyzed KYNA production. More-
over, methionine and glutamine show inhibitory eﬀects on KAT
activity, while cysteine functions as either an antagonist or an
inhibitor depending on the concentration. Therefore, the overall
level of keto acids and cysteine might modulate the KYNA
synthesis. Results from this study will be useful in the study of
KAT regulation in other animals.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In mammals, kynurenic acid (KYNA) functions as a broad-
spectrum antagonist of ionotropic excitatory amino acid re-
ceptors, which protects the central nervous system (CNS) from
being overstimulated by excitatory cytotoxins, and its inhibi-
tory actions underlie its neuroprotective and anticonvulsant
eﬀects [1–4]. Fluctuations in endogenous brain KYNA levels
greatly inﬂuence neuronal excitation and vulnerability to ex-
citotoxic attack [5–8]. It is apparent that KYNA is critical for
maintaining normal physiological functions of the CNS in
mammals. Indeed, it has been proposed that altered KYNA
metabolism might play a role in seizure phenomena and neu-
rodegenerative processes associated with excessive activation
of glutamate receptors [9].
In the CNS, KYNA synthesis occurs primarily in glial cells,
due to the conversion of its immediate bioprecursor, kynu-
renine, by kynurenine aminotransferases (KATs) [10]. At least
two distinct KATs (KAT I and KAT II) were described in
human and rodent brains [11,12]. KAT I is located in forebrain
astrocytes [13], and also in a small percentage of neurons, such* Corresponding author. Fax: +1-217-244-7421.
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encoding for a soluble protein with KAT I activity has been
isolated from a rat brain library [15], suggesting that KAT I
plays a role in the brain KYNA production. Moreover,
mammalian KAT I is identical to glutamine transaminase K
and is also a cysteine S-conjugate b-lyase [16].
KYNA production is likely aﬀected by a number of factors,
including the concentration of KAT and the concentration of
KAT substrates, products and potential inhibitors. To achieve
a comprehensive understanding of the mechanisms maintain-
ing a physiological level of endogenous KYNA in living or-
ganisms, it is essential to critically evaluate the factors aﬀecting
KAT activity. Our laboratory has been focusing on trypto-
phan metabolism in mosquitoes and mainly on the kynurenine
pathway. Based on the studies of the involved enzymes, tryp-
tophan dioxygenase (Li, et al., unpublished data), kynurenine
monooxygenase [17], Aedes aegypti KAT (AeKAT) [18], and
3-hydoxykynurenine transaminase [19,20], mosquitoes have a
similar kynurenine pathway in the production of KYNA as
that in mammals. By studying AeKAT, a homolog of the
mammalian KAT I, we demonstrated its transcriptional up-
regulation in the mosquito adult brain, suggesting that it might
play a role in CNS functions [18]. Although KAT I has been
implicated in KYNA production in the mammalian brain
[13–15], it is generally agreed that quantitatively the role of
KAT I is minor [2], and some authors, e.g. [16], have ques-
tioned whether KAT I contributes at all to KYNA production
in the mammalian brain. However, our work has provided
strong evidence that the mosquito equivalent to KAT I might
indeed contribute to KYNA production in the insect’s brain. It
is anticipated that through extensive characterization of the
enzyme, we may better understand the physiological functions
and molecular regulation of this group of enzymes. After
screening the eﬀects of various amino acids and keto acids on
AeKAT catalyzed kynurenine transamination, we found that
cysteine signiﬁcantly enhanced kynurenine to KYNA pathway
within a certain range of concentrations, but inhibited the
pathway when its concentration was above a certain level. In
addition, AeKAT was active to most keto acids, but due to
substrate inhibition, their concentrations could have a major
impact on AeKAT activity. Results from this study provide
some basis for suggesting the potential regulatory roles keto
acids and cysteine might play in KYNA biosynthesis. These
data should be highly useful in comparative studies between
AeKAT and its mammalian homologs and for a better
understanding of the regulatory mechanisms of KYNA
production in the CNS.blished by Elsevier B.V. All rights reserved.
Table 1
Kinetic parameters of AeKAT towards diﬀerent amino acids
Amino acids Km
(mM)
kcat
(min1)
kcat=Km
(min1 mM1)
Cysteine 1.3 0.6 206 19 159
Tyrosine 0.9 0.2 139 10 155
Glutamine 3.8 0.8 561 34 148
Methionine 1.4 0.4 163 10 117
Histidine 1.5 0.3 168 10 112
Phenylalanine 3.5 0.3 283 10 81
Kynurenine 4.3 0.5 172 10 40
Asparagine 6.1 0.8 230 10 38
Tryptophan 12.9 4.2 283 38 22
Leucine 34.5 7.5 758 62 22
Serine 32.7 7.9 345 43 11
Alanine 246 164 1540 782 6
Amino-butyrate 92.7 15.9 317 34 3
The activities were measured as described in Section 2.2. The reaction
mixture contains 0.4–100 mM of a diﬀerent amino acid, 10 mM ke-
tobutyrate or pyruvate (only for amino-butyrate). The kinetic pa-
rameters of the enzyme to amino acids were calculated by ﬁtting the
experimental data to the Michaelis–Menten equation using the En-
zyme Kinetics Module (SPSS Science).
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2.1. Recombinant KAT expression and puriﬁcation
AeKAT (NCBI accession number AF395204) was expressed in an
insect cell line/baculovirus expression system and subsequently puriﬁed
through diﬀerent chromatography methods [18]. The purity of the
enzyme was assessed by SDS–PAGE analysis. Protein concentration
was determined by a Bio-Rad protein assay kit using bovine serum
albumin as a standard. Puriﬁed recombinant AeKAT was used for
biochemical assays.
2.2. Biochemical characterization
All chemicals were purchased from Sigma unless otherwise speciﬁed.
The stock solution for amino acids (L-form) and keto acids was pre-
pared in 100 mM Tris, adjusted to pH 8.5 before being used for en-
zyme activity assay. KAT activity assay was based on the described
method [18]. Brieﬂy, a reaction mixture of 50 ll containing 15 mM
kynurenine, 0.16–20 mM diﬀerent keto acids, 40 lM pyridoxal 50-
phosphate (PLP), and 2 lg puriﬁed recombinant AeKAT was prepared
using a 100 mM Tris buﬀer, pH 8.5. The mixture was incubated for 10
min at 45 C and the reaction was stopped by adding an equal volume
of 0.8 M formic acid. Supernatant was obtained by centrifugation of
the reaction mixture at 15 000· g at 4 C for 10 min and analyzed by
HPLC-UV at 330 nm for KYNA.
To determine the eﬀect of cysteine on AeKAT activity, a varying
concentration of cysteine from 0.02 to 40 mM was added to the re-
action mixture containing 3 mM kynurenine and 2 mM ketobutyrate,
and the enzyme activity was assayed in the same manner. To determine
possible transamination activity and kinetics of AeKAT towards other
amino acids, the same reaction condition was used except with the
reaction mixture containing 0.4–100 mM of a diﬀerent amino acid, 10
mM ketobutyrate or pyruvate. The product was quantiﬁed based on
the detection of o-phthaldialdehyde thiol (OPT)–amino acid product
conjugate by HPLC with electrochemical detection after their corre-
sponding reaction mixtures were derivatized by OPT reagent [20,21].
All assays were performed at least in triplicate. The results for the
eﬀects of keto acids and amino acids were analyzed by a student t test.
The kinetic parameters of the recombinant enzyme towards diﬀerent
amino acids or keto acids were calculated by ﬁtting the experimental
data to the Michaelis–Menten equation using the Enzyme Kinetics
Module (SPSS Science). Protein was assayed by a Bio-Rad protein
assay kit using bovine serum albumin as a standard.3. Results
3.1. Substrate study of AeKAT
AeKAT was tested for aminotransferase activity towards 20
protein amino acids, aminoadipate, aminobutyrate, kynuren-
ine and 3-hydroxykynurenine using ketobutyrate or pyruvate
as an amino acceptor. The enzyme displayed fairly high ac-
tivity towards a number of amino acids (Table 1). Based on the
parameter of kcat/Km, it is clear that AeKAT is very eﬃcient in
catalyzing the transamination of cysteine, tyrosine, glutamine,
methionine, histidine, phenylalanine and kynurenine (Table 1),
which is consistent with the previous studies showing that
glutamine transaminase K has activity towards glutamine,
methionine, aromatic amino acids, and cysteine, but poor af-
ﬁnity towards alanine [22–24].
Fourteen keto acids were tested for their potential as amino
group acceptors for AeKAT with 15 mM kynurenine as the
amino group donor. Among them, twelve keto acids displayed
high activity and two (ketoadipate and ketovaline) showed low
activity (Fig. 1). Unlike amino group donors, however, all keto
acids, with exception of ketobutyrate, showed substrate inhi-
bition at relatively high concentration, especially p-hydroxy-
phenylpyruvate, glyoxylate, and a-keto-methylthiobutyric acid
(aKMB) with substrate inhibition starting at 1.3 mM (Fig. 1).
Pyruvate and ketoglutarate were the most commonly usedamino group acceptors; however, they were apparently not
eﬃcient amino group acceptors for AeKAT. Similar results
have also been observed in previous studies of glutamine
transaminase K: i.e., it generally had wide a-keto acid speci-
ﬁcity, high activity with aKMB and glyoxylate, poor aﬃnity
towards pyruvate and strong substrate inhibition by aKMB
and phenylpyruvate [22,23,25].3.2. Eﬀects of amino acids on AeKAT catalyzed kynurenine
transamination
Based on the Km of AeKAT to the amino acids, cysteine,
tyrosine, glutamine, methionine, histidine and phenylalanine
have either similar or better aﬃnity to AeKAT than kynu-
renine; accordingly, the presence of any of these amino acids in
the kynurenine/AeKAT/keto acid mixture should lead to
competitive inhibition of AeKAT activity towards kynurenine.
When 2 mM of a diﬀerent amino acid was incorporated into
the kynurenine/AeKAT/ketobutyrate reaction mixture with
kynurenine concentration at 3 mM, the rate of KYNA pro-
duction was signiﬁcantly decreased in the presence of gluta-
mine, methionine and histidine. Surprisingly, however, no
signiﬁcant inhibition was observed in the presence of tyrosine
and phenylalanine (Fig. 2). KYNA production was not seri-
ously aﬀected in the presence of other competing amino acids.
These ﬁndings require further study.
3.3. Eﬀects of keto acids on AeKAT activity
The ability of a number of biologically relevant keto acids
to function as the amino group acceptors for AeKAT indi-
cated that their presence might have some combined eﬀect on
KYNA production. To test this hypothesis, diﬀerent keto
acids were incorporated into the kynurenine/AeKAT/keto-
butyrate mixture and the rate of KYNA production was
compared to that of the control reaction mixture in the ab-
sence of the additional amino group acceptor(s). Results
showed that pyruvate and phenylpyruvate had no signiﬁcant
eﬀect on KYNA production, p-hydroxy-phenylpyruvate and
aKMB decreased KYNA production, and the other tested
keto acids at the applied concentration (2 mM) increased
Fig. 1. Cosubstrate speciﬁcity of AeKAT. AeKAT was incubated in
the presence of 15 mM kynurenine and 0.16–20 mM diﬀerent keto
acids. The activity was quantitated by the amount of KYNA produced
in the reaction mixture. The units are labeled at the right corner.
Fig. 2. Eﬀect of other amino acids on enzyme activity. Assay condi-
tions were similar to those described in Section 2.2, except that kyn-
urenine and ketobutyrate concentrations were 3 and 2 mM,
respectively. The concentration of the additional amino acid incor-
porated into the reaction mixture was 2 mM. The activity was quan-
titated by the amount of KYNA produced in the reaction mixture. The
star labeled bars are signiﬁcantly diﬀerent from that of the control
without additional amino acid. *P < 0:5, **P < 0:01.
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and pyruvate showed no substrate inhibition to AeKAT at
physiological concentration (see Fig. 1). When these three
keto acids each at 1 mM concentration were incorporated
together into a kynurenine/AeKAT reaction mixture, the rate
of KYNA production was higher than with each keto acid
alone at 1 mM in the same reaction mixture (Fig. 3(b)),
suggesting that the overall level and contents of keto acids
may modulate KYNA biosynthesis. In contrast, glyoxylate,
aKMB and p-hydroxy-phenylpyruvate showed substrate in-
hibition at 1.3 mM (see Fig. 1). When these three keto acids
at 2 mM ﬁnal concentration each were incorporated into the
kynurenine/AeKAT reaction mixture, production of KYNA
was much lower than with each keto acid alone at 2 mM in
the same kynurenine/AeKAT reaction mixture (Fig. 3(c)),
which again suggests that the overall level of keto acids
modulates KYNA biosynthesis.Fig. 3. Eﬀect of the multiple keto acids on AeKAT-catalyzed KYNA
production. (a) Rate of KYNA production in the AeKAT and kynu-
renine mixture in the presence of 3 mM of ketobutyrate and 2 mM of a
diﬀerent keto acids. The star labeled bars are signiﬁcantly diﬀerent
from the bar for the control without adding any other keto acid.
*P < 0:5, **P < 0:01. (b) Inhibition of KYNA production in the Ae-
KAT/kynurenine mixture in the presence of three keto acids, aKMB,
glyoxylate, and p-hydroxy-phenylpyruvate. They were used either si-
multaneously at 2 mM each (combination) or 2 mM any one of them
alone. (c) Enhancement of KYNA production by AeKAT in the
presence of three diﬀerent keto acids, pyruvate, ketoglutarate and
oxaloacetate. They were used either simultaneously at 1 mM each
(combination) or 1 mM any one of them alone. HPP, p-hydroxy-
phenylpyruvate.
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Cysteine is one of the favorable amino group donors for
AeKAT, but the presence of 2 mM cysteine in the kynurenine/
AeKAT reaction mixture resulted in more than a 2-fold in-
crease in the rate of KYNA production (Fig. 2). When varying
concentrations of cysteine from 0.02 to 40 mM were incor-
porated into kynurenine/AeKAT/ketobutyrate reaction mix-
tures with kynurenine and ketobutyrate at 3 and 2 mM,
respectively, the rate of KYNA production was not substan-
tially changed with cysteine concentration from 0.02 to 0.16
mM, was signiﬁcantly increased with cysteine concentration
from 0.31 to 2.5 mM, and was greatly decreased with cysteine
concentration at and above 5 mM (Fig. 4).4. Discussion
KYNA functions as a broad-spectrum antagonist against
excitatory cytotoxins in the CNS [2,3] and is derived from
kynurenine by transaminase-mediated reactions. Factors af-
fecting KAT activity undoubtedly inﬂuence KYNA biosyn-
thesis. It has been established that in humans, KAT I is
suggested as one of at least two KATs responsible for KYNA
production in the brain [12,26,27]. There have been a number
of studies dealing with the biochemical characterization of
mammalian and human KAT I [11,15,26–29]. However, most
studies used partially puriﬁed enzymes from diﬀerent species,
so that the amount of the enzyme available and the purity of
the protein for extensive characterization were often limiting
factors. Under in vivo conditions, multiple amino group do-
nors and acceptors are likely to co-exist with KAT in the local
environment, so that KAT activity may be continuously ﬁne-
tuned by the levels of these components. Understanding the
factors that modulate KAT activity could provide insight into
strategies for maintaining physiological KYNA concentrations
under disease conditions. Using a baculovirus/insect cell ex-
pression system, we were able to express and purify a large
quantity (in mg level each time) of pure AeKAT, which en-
abled us to perform extensive biochemical characterization of
the enzyme. Our data revealed some details in the biochemical
behavior of AeKAT towards various amino acids and ketoFig. 4. Eﬀect of cysteine on enzyme activity. Assay conditions were
similar to those described in Section 2.2. The activity was calculated by
the amount of KYNA produced in the reaction mixture. The bars
labeled with stars are signiﬁcantly diﬀerent from the bar for the control
without adding any cysteine. *P < 0:5, **P < 0:01.acids, which should be essential towards a comprehensive
understanding of KAT in living organisms.
Mammalian KAT I is identical to glutamine transaminase
K and a cysteine S-conjugate b-lyase that is found mainly in
kidney and liver [16], but in arthropods KAT activity or
mRNA is mainly present in the adult head [18,30,31], which
suggests that the enzyme primarily functions in CNS. It has
been shown that the concentration of kynurenine in the brain
is in lM range [32,33], which leads to a question about the
eﬃciency of KAT in mediating KYNA biosynthesis in the
brain. Many aspects of brain amino acid metabolism are
sharply compartmented, with a particular metabolic pathway
or transport process being restricted to either astrocytes or
neurons [34]. In recent years, there have been a number of
studies providing strong evidence of intracellular compart-
mentation of metabolism in both astrocytes and neurons in
the brain (see reviews: [35–37] and references therein). Kyn-
urenine may be present at a relatively high concentration
locally at some sites in the brain, so that the mean kynu-
renine concentration in the brain might hardly reﬂect the
true kynurenine concentration in speciﬁc sites where the
kynurenine to KYNA pathway operates. Similar consider-
ations apply to many neuroactive agents in the CNS [38]. An
unexpected phenomenon in the study of diﬀerent amino acids
on KYNA production is the eﬀect of cysteine on enhancing
AeKAT-catalyzed KYNA production. Cysteine itself was a
favorable amino group donor for AeKAT. Depending upon
cysteine concentrations, its addition to the reaction mixture
should, in principle, decrease the rate of KYNA production.
The inability to substantially change the rate of KYNA
production in the presence of low concentrations (0.02–0.16
mM) of cysteine and strong inhibition of KYNA production
in the presence of high concentrations (5–40 mM) of cysteine
can be logically explained by the status of AeKAT saturation
by cysteine. Cysteine may also form a covalent ring structure
with PLP cofactor, or form hemithioketals with a-keto acids
that are stable enough to be crystallized [24], which might
also contribute to the inhibition of KAT activity. However,
the apparent increase in the rate of KYNA production in the
presence of 0.31–2.5 mM cysteine was unexpected. The ef-
fects of cysteine on AeKAT in vitro suggest that further
study is needed to elucidate the in vivo role of cysteine in
regulation of the KYNA production in mosquitoes.
Some keto acids were found to regulate KYNA production
in the rat brain [39,40], but the mechanism was not fully
understood. Our data clearly showed that most keto acids
could serve as amino group acceptors for AeKAT and that a
combination of diﬀerent keto acids could have either a po-
sitive or negative impact on AeKAT mediated kynurenine
transamination. Unlike amino group donors, most of the
tested keto acids showed substrate inhibition to AeKAT at
and above a certain concentration; therefore, the applied keto
acid concentration in the reaction mixture could greatly aﬀect
the rate of KYNA production. This is practically important,
because aKMB, glyoxylate and p-hydroxy-phenylpyruvate
could easily be concluded to be poor amino group acceptors
for the enzyme if 5–10 mM concentrations of these keto acids
(commonly used substrate concentrations for transaminase
assay) were used for the initial screening. Among the keto
acids tested, ketobutyrate was found to be the only one
showing no substrate inhibition at the tested concentrations;
therefore, it was often used as the primary amino group ac-
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more than one amino group acceptor at their optimal con-
centrations enhances AeKAT mediated KYNA production.
For example, pyruvate, oxaloacetate and ketoglutarate
showed no apparent substrate inhibition to AeKAT up to 10
mM in the reaction mixture. When a combination of these
three keto acids at 1 mM each was added into the AeKAT/
kynurenine mixture, the rate of KYNA production was much
greater than any one of them alone, indicating that diﬀerent
keto acids are able to jointly function as the amino group
acceptor for AeKAT. In contrast, some keto acids displayed
substrate inhibition at relatively low concentrations, and a
combination of these amino acids aggravated the inhibitory
eﬀect to AeKAT. For example, glyoxylate, aKMB and p-
hydroxy-phenylpyruvate displayed substrate inhibition at 1.3
mM. When all three keto acids were present in the enzyme
reaction mixture, the rate of KYNA production was signiﬁ-
cantly lower than any single keto acid alone at the same re-
action condition. This result points out that the amino group
acceptor is also a rate-limiting factor during KAT mediated
transamination reactions.
In summary, our data revealed that AeKAT is a multi-
functional aminotransferase as has been shown for other
mammalian KATs [16]. Most naturally occurring keto acids
can serve as the amino group acceptor for AeKAT and the
presence of multiple keto acids could either enhance or reduce
the kynurenine to KYNA pathway, depending on their con-
centrations, and cysteine may function as an important en-
dogenous AeKAT modulator in insects. The results, especially
the enhancement eﬀect of cysteine and inhibitory eﬀects of
some keto acids, should be critical for a comprehensive un-
derstanding of KATs, serve as a useful reference for compar-
ative studies among KATs from diﬀerent resources, and
provide insight into novel therapeutic compounds to upregu-
late endogenous KYNA levels in the brain. The availability of
an adequate amount of native AeKAT has led to the successful
crystallization of AeKAT and its crystals diﬀract at a resolu-
tion of 2.0 A. We anticipate achieving better understanding of
the structure function relationship for AeKAT once its crystal
structure is determined.Acknowledgements: This study was supported by the National Insti-
tutes of Health Grant AI 44399. The authors thank all the reviewers
for their valuable comments on the manuscript.References
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